globenewswire news

Transactions under Novonesis’ share buyback program

2026-10-26T13:25:52Z

Please read the announcement in PDF

Attachment

2026_25_Share_buyback

Articles

Fangzhou’s AI-Powered Supply Chain Platform Recognized in 2026 for Pharmaceutical Distribution Best Practices

2026-10-27T07:40:53Z

GUANGZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, was recently recognized for its AI-powered...

Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026

2026-10-27T07:15:00Z

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of...

KFSH Strengthens Patient-Centered Care With ICHOM Accreditation

2026-10-27T07:00:00Z

RIYADH, Saudi Arabia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has earned Level 1 accreditation from the International Consortium for Health Outcomes Measurement...

Purespring Therapeutics advances kidney-targeted gene therapy PS-003 towards the clinic in X-linked Alport Syndrome, with new preclinical and epidemiological data presented at ASN Kidney Week 2026

2026-10-27T07:00:00Z

London, UK, 27 October 2026 – Purespring Therapeutics, a precision nephrology company, pioneering podocyte-targeted, genetically-driven therapies where unmet need is greatest, today announces new preclinical data for PS-003, a novel...

Major shareholder announcement

2026-10-27T07:00:00Z

Company announcement no. 42 - 2627 October 2026

ONWARD Medical to Announce Third-Quarter 2026 Results on November 3, 2026

2026-10-27T06:30:00Z

EINDHOVEN, The Netherlands, Oct. 27, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence...

Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories

2026-10-27T06:00:00Z

Basel, 27 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received the CE Mark for its cobas smart e immunoanalyser, a compact, standalone platform...

Idorsia seeks US label update for QUVIVIQ daytime functioning benefits – first patients enrolled in Dari-Dream

2026-10-27T06:00:00Z

Building on established clinical evidence, Dari-Dream is designed to further characterize the impact of QUVIVIQ on daytime functioning and support its inclusion in the US prescribing information.

Basilea raises full-year guidance 2026 and financial target for “Agenda 2030” and provides updates on late-stage clinical programs

2026-10-27T06:00:00Z

Ad hoc announcement pursuant to Art. 53 LR

Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance

2026-10-27T06:00:00Z

Ad hoc announcement pursuant to Art. 53 LR

Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

2026-10-27T06:00:00Z

Leiden, the Netherlands, October 27, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, presents its preliminary (unaudited) financial report...

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

2026-10-27T00:00:00Z

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces an expert webcast, co-hosted with Citigroup Global Markets...

Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026

2026-10-26T21:05:00Z

Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026

Onconetix Announces Reverse Stock Split

2026-10-26T21:03:00Z

CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of...

Onco360® Has Been Selected as a National Pharmacy Partner for ZEGFROVY® (sunvozertinib)

2026-10-26T21:00:00Z

LOUISVILLE, Ky., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by AstraZeneca Pharmaceuticals for Zegfrovy® (sunvozertinib), which...

Octane Biotech and Currus Biologics Automate Manufacturing of CUR-001 CAR T-Cell Therapy on the Cocoon® Platform

2026-10-26T21:00:00Z

Automated, closed-system process to support Currus’ Phase 1 trial in mesothelin-positive solid tumours, with first patient dosing expected in early 2027

SL Science Holding Limited Reports First Half 2026 Financial Results

2026-10-26T20:15:00Z

Net revenue rose 23% to $1.39 million with gross margin expanding to 40.2%, driven by B2B distribution growth and reduction in purchase costs compared with last period due to establishment...

Park Dental Partners Announces Dates for Third Quarter 2026 Earnings Release and Conference Call

2026-10-26T20:13:00Z

MINNEAPOLIS, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading dental resource organization, today announced that it will report its financial results for the quarter...

Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2026-10-26T20:12:29Z

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed...

Clover Health to Participate in Upcoming UBS Global Healthcare Conference

2026-10-26T20:05:00Z

WILMINGTON, Del., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Interim Chief Financial Officer, Clay Thornton,...

OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th

2026-10-26T20:05:00Z

BETHLEHEM, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its third quarter 2026 financial results on Monday, November 9, 2026,...